NCT04415944 2026-03-19
HIPEC
Wake Forest University Health Sciences
Phase 2 Completed
Clinical Trials
13 trialsNCT06412510 2026-03-18
Prehabilitation for EOC, Fallopian Tube, Primary Peritoneal Carcinoma and Pancreatic Cancer w/ NACT
Case Comprehensive Cancer Center
Phase 1/2 Recruiting
NCT07480954 2026-03-18
DUAL-OV-CAR-NK
Beijing Biotech
Phase 1/2 Recruiting
NCT05763199 2026-03-12
Standardized Extract of Cultured Lentinula Edodes Mycelia (AHCC®) in Ovarian Cancer Patients on Adjuvant Chemotherapy
University of California, Davis
Phase 2 Active not recruiting
NCT05116189 2026-03-09
KEYNOTE-B96
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT07454018 2026-03-06
Iparomlimab/Tuvonralimab + Standard Chemotherapy and Olaparib in Platinum-Sensitive Recurrent Ovarian Cancer
The First Affiliated Hospital of Soochow University
Phase 2 Not yet recruiting
NCT06819007 2026-03-05
DO-01
Daiichi Sankyo
Phase 3 Recruiting
NCT03393884 2026-02-27
OVATION 2
Imunon
Phase 1/2 Active not recruiting
NCT06240598 2026-02-27
A Study of Second Look Laparoscopy (SLL) in People With Ovarian Cancer Who Have Completed Their First Course of Chemotherapy
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT06915025 2026-02-27
OVATION-3
Imunon
Phase 3 Recruiting
NCT07432633 2026-02-25
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
Blue Earth Diagnostics
Phase 1/2 Recruiting
NCT06890338 2026-02-24
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
AbbVie
Phase 2 Recruiting
NCT07334119 2026-02-19
Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors
Myeloid Therapeutics
Phase 1 Recruiting